Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$13,571 Mln
P/E Ratio
12.05
P/B Ratio
2.03
Industry P/E
--
Debt to Equity
0.05
ROE
0.19 %
ROCE
17.8 %
Div. Yield
0 %
Book Value
132.32
EPS
24.54
CFO
$5,562.10 Mln
EBITDA
$7,707.44 Mln
Net Profit
$5,310.71 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
United Therapeutics (UTHR)
| -14.76 | -2.02 | -18.90 | 28.61 | 18.81 | 22.34 | 6.30 |
|
BSE Sensex*
| 2.55 | 3.65 | 4.54 | 7.46 | 12.04 | 19.65 | 11.41 |
|
S&P Midcap 400
| -8.37 | -2.02 | -11.96 | -1.34 | 3.58 | 11.87 | 6.46 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
United Therapeutics (UTHR)
| 59.84 | -20.93 | 28.70 | 42.35 | 72.33 | -19.12 | -26.27 |
|
S&P Midcap 400
| 12.12 | 14.45 | -14.48 | 23.21 | 11.81 | 24.05 | -12.43 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 257.19 | 32,984.47 | -- | 362.29 | |
| 131.87 | 14,047.06 | -- | -8.58 | |
| 153.45 | 26,540.58 | 20.07 | 22.55 | |
| 23.62 | 17,785.46 | -- | -94.9 |
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.... The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company involved in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. United Therapeutics Corporation was incorporated in 1996 and is headquartered in Silver Spring, Maryland. Address: 1000 Spring Street, Silver Spring, MD, United States, 20910 Read more
Founder, Chairman & CEO
Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.
Founder, Chairman & CEO
Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.
Headquarters
Silver Spring, MD
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of United Therapeutics Corporation (UTHR) stood at $ 7,364 Mln as on 31-Dec-24
The share price of United Therapeutics Corporation (UTHR) is $300.76 (NASDAQ) as of 29-Apr-2025 16:00 EDT. United Therapeutics Corporation (UTHR) has given a return of 18.81% in the last 3 years.
United Therapeutics Corporation (UTHR) has a market capitalisation of $ 13,571 Mln as on 29-Apr-2025. As per Value Research classification, it is a Mid Cap company.
The P/E ratio of United Therapeutics Corporation (UTHR) is 12.05 times as on 29-Apr-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the United Therapeutics Corporation (UTHR) and enter the required number of quantities and click on buy to purchase the shares of United Therapeutics Corporation (UTHR).
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company involved in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. United Therapeutics Corporation was incorporated in 1996 and is headquartered in Silver Spring, Maryland. Address: 1000 Spring Street, Silver Spring, MD, United States, 20910
The CEO & director of Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.. is United Therapeutics Corporation (UTHR), and CFO & Sr. VP is Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D..
There is no promoter pledging in United Therapeutics Corporation (UTHR).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
3,132
|
|
|
2,593
|
|
|
2,451
|
|
|
1,405
|
| United Therapeutics Corporation (UTHR) | Ratios |
|---|---|
|
Return on equity(%)
|
19.23
|
|
Operating margin(%)
|
54.98
|
|
Net Margin(%)
|
41.53
|
|
Dividend yield(%)
|
--
|
Yes, TTM profit after tax of United Therapeutics Corporation (UTHR) was $1,195 Mln.
$3.72
(
